REPORT ID 2832

China Antidiabetic SGLT-2 Inhibitor Market Research Report 2017

Publish Date
11-Dec-17
Pages
112
Format
Electronic (PDF)

The global Antidiabetic SGLT-2 Inhibitor market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

China plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2022, with a CAGR of xx%.

This report studies the Antidiabetic SGLT-2 Inhibitor development status and future trend in China, focuses on top players in China, also splits Antidiabetic SGLT-2 Inhibitor by type and by applications, to fully and deeply research and reveal the market general situation and future forecast.

The major players in China market include
    Pfizer
    AstraZeneca
    Johnson & Johnson
    GlaxoSmithKline
    Merck & Co
    Eli Lilly
    Sanofi
    Takeda Pharmaceuticals
    Novo Nordisk
    Servier Laboratories
    Boehringer Ingelheim
    Bristol-Myers Squibb

Geographically, this report splits the China market into six regions,
    South China
    East China
    Southwest China
    Northeast China
    North China
    Central China
    Northwest China

On the basis of product, this report displays the sales volume (K Pcs), revenue (Million USD), product price (USD/Pcs), market share and growth rate of each type, primarily split into
    Canagliflozin
    Empagliflozin
    Dapagliflozin
    Other

On the basis of the end users/application, this report covers
    Hospitals
    Clinics
    Other

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

China Antidiabetic SGLT-2 Inhibitor Market Research Report 2017
1 Antidiabetic SGLT-2 Inhibitor Overview
    1.1 Product Overview and Scope of Antidiabetic SGLT-2 Inhibitor
    1.2 Classification of Antidiabetic SGLT-2 Inhibitor by Product Category
        1.2.1 China Antidiabetic SGLT-2 Inhibitor Sales (K Pcs) Comparison by Type (2012-2022)
        1.2.2 China Antidiabetic SGLT-2 Inhibitor Sales (K Pcs) Market Share by Type in 2016
        1.2.3 Canagliflozin
        1.2.4 Empagliflozin
        1.2.5 Dapagliflozin
        1.2.6 Other
    1.3 China Antidiabetic SGLT-2 Inhibitor Market by Application/End Users
        1.3.1 China Antidiabetic SGLT-2 Inhibitor Sales (K Pcs) and Market Share Comparison by Applications (2012-2022)
        1.3.2 Hospitals
        1.3.3 Clinics
        1.3.4 Other
    1.4 China Antidiabetic SGLT-2 Inhibitor Market by Region
        1.4.1 China Antidiabetic SGLT-2 Inhibitor Market Size (Million USD) Comparison by Region (2012-2022)
        1.4.2 South China Antidiabetic SGLT-2 Inhibitor Status and Prospect (2012-2022)
        1.4.3 East China Antidiabetic SGLT-2 Inhibitor Status and Prospect (2012-2022)
        1.4.4 Southwest China Antidiabetic SGLT-2 Inhibitor Status and Prospect (2012-2022)
        1.4.5 Northeast China Antidiabetic SGLT-2 Inhibitor Status and Prospect (2012-2022)
        1.4.6 North China Antidiabetic SGLT-2 Inhibitor Status and Prospect (2012-2022)
        1.4.7 Central China Antidiabetic SGLT-2 Inhibitor Status and Prospect (2012-2022)
    1.5 China Market Size (Sales and Revenue) of Antidiabetic SGLT-2 Inhibitor (2012-2022)
        1.5.1 China Antidiabetic SGLT-2 Inhibitor Sales (K Pcs) and Growth Rate (%)(2012-2022)
        1.5.2 China Antidiabetic SGLT-2 Inhibitor Revenue (Million USD) and Growth Rate (%)(2012-2022)

2 China Antidiabetic SGLT-2 Inhibitor Market Competition by Players/Manufacturers
    2.1 China Antidiabetic SGLT-2 Inhibitor Sales and Market Share of Key Players/Manufacturers (2012-2017)
    2.2 China Antidiabetic SGLT-2 Inhibitor Revenue and Share by Players/Manufacturers (2012-2017)
    2.3 China Antidiabetic SGLT-2 Inhibitor Average Price (USD/Pcs) by Players/Manufacturers (2012-2017)
    2.4 China Antidiabetic SGLT-2 Inhibitor Market Competitive Situation and Trends
        2.4.1 China Antidiabetic SGLT-2 Inhibitor Market Concentration Rate
        2.4.2 China Antidiabetic SGLT-2 Inhibitor Market Share of Top 3 and Top 5 Players/Manufacturers
        2.4.3 Mergers & Acquisitions, Expansion in China Market
    2.5 China Players/Manufacturers Antidiabetic SGLT-2 Inhibitor Manufacturing Base Distribution, Sales Area, Product Types

3 China Antidiabetic SGLT-2 Inhibitor Sales and Revenue by Region (2012-2017)
    3.1 China Antidiabetic SGLT-2 Inhibitor Sales (K Pcs) and Market Share by Region (2012-2017)
    3.2 China Antidiabetic SGLT-2 Inhibitor Revenue (Million USD) and Market Share by Region (2012-2017)
    3.3 China Antidiabetic SGLT-2 Inhibitor Price (USD/Pcs) by Regions (2012-2017)

4 China "&B1&" Sales and Revenue by Type/ Product Category (2012-2017)"
    4.1 China Antidiabetic SGLT-2 Inhibitor Sales (K Pcs) and Market Share by Type/ Product Category (2012-2017)
    4.2 China Antidiabetic SGLT-2 Inhibitor Revenue (Million USD) and Market Share by Type (2012-2017)
    4.3 China Antidiabetic SGLT-2 Inhibitor Price (USD/Pcs) by Type (2012-2017)
    4.4 China Antidiabetic SGLT-2 Inhibitor Sales Growth Rate (%) by Type (2012-2017)

5 China "&B1&" Sales by Application (2012-2017)"
    5.1 China Antidiabetic SGLT-2 Inhibitor Sales (K Pcs) and Market Share by Application (2012-2017)
    5.2 China Antidiabetic SGLT-2 Inhibitor Sales Growth Rate (%) by Application (2012-2017)
    5.3 Market Drivers and Opportunities

6 China Antidiabetic SGLT-2 Inhibitor Players/Suppliers Profiles and Sales Data
    6.1 Pfizer
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Antidiabetic SGLT-2 Inhibitor Product Category, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Pfizer Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 AstraZeneca
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Antidiabetic SGLT-2 Inhibitor Product Category, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 AstraZeneca Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Johnson & Johnson
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Antidiabetic SGLT-2 Inhibitor Product Category, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 GlaxoSmithKline
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Antidiabetic SGLT-2 Inhibitor Product Category, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Merck & Co
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Antidiabetic SGLT-2 Inhibitor Product Category, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Merck & Co Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Eli Lilly
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Antidiabetic SGLT-2 Inhibitor Product Category, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Eli Lilly Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Sanofi
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Antidiabetic SGLT-2 Inhibitor Product Category, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Sanofi Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Takeda Pharmaceuticals
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Antidiabetic SGLT-2 Inhibitor Product Category, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Novo Nordisk
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Antidiabetic SGLT-2 Inhibitor Product Category, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.9.4 Main Business/Business Overview
    6.10 Servier Laboratories
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Antidiabetic SGLT-2 Inhibitor Product Category, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million USD), Price (USD/Pcs) and Gross Margin (%)(2012-2017)
        6.10.4 Main Business/Business Overview
    6.11 Boehringer Ingelheim
    6.12 Bristol-Myers Squibb

7 Antidiabetic SGLT-2 Inhibitor Manufacturing Cost Analysis
    7.1 Antidiabetic SGLT-2 Inhibitor Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Antidiabetic SGLT-2 Inhibitor

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Antidiabetic SGLT-2 Inhibitor Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Antidiabetic SGLT-2 Inhibitor Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 China Antidiabetic SGLT-2 Inhibitor Market Size (Sales and Revenue) Forecast (2017-2022)
    11.1 China Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (Million USD) Forecast (2017-2022)
    11.2 China Antidiabetic SGLT-2 Inhibitor Sales (K Pcs) Forecast by Type (2017-2022)
    11.3 China Antidiabetic SGLT-2 Inhibitor Sales (K Pcs) Forecast by Application (2017-2022)
    11.4 China Antidiabetic SGLT-2 Inhibitor Sales (K Pcs) Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Methodology and Data Source
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer
    13.4 Author List